Skip to content

Merit Medical Systems MMSI Therapeutic — Revenue

Other product segments

Foundational
$255.48M

Similar metrics at other companies

Lantheus Holdings logo
LNTHProduct — Revenue
$369.85M+0.8%
LQD
LQDAProduct — Revenue
$129.88M
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
Kiniksa Pharmaceuticals International, plc logo
KNSAProduct — Revenue
$214.27M+55.5%
Axsome Therapeutics logo
AXSMProduct — Revenue
$189.4M+57.4%
Catalyst Pharmaceutical logo
CPRXProduct Revenue Net — Revenue
$149.34M+5.6%

Other financials

Income statement

See full
Revenue$381.9M+7.5%
Gross profit$184.8M+7.4%
Operating income$44.2M+7.6%
Net income$41.0M+36.0%
EPS (diluted)$0.68+38.8%

Balance sheet

See full
Cash & equivalents$488.1M+23.4%
Total debt$821.6M+0.5%
Total equity$1.6B+13.9%
Total assets$2.7B+10.2%

Cash flow

See full
Operating cash flow$40.7M+0.3%
CapEx$16.0M-24.0%
Free cash flow$24.7M+26.5%

Valuation

See full
Market cap$4.01B-34.1%
Enterprise value$4.34B-33.3%
P/E28.8×-21.0×
P/S2.6×-1.8×

Profitability

See full
Gross margin48.7%+0.9pp
Operating margin12.2%+0.6pp
Net margin9%+0.2pp
FCF margin14.3%+1.3pp

Returns & leverage

See full
Return on equity9.1%0.0pp
Debt / equity0.5×-0.1×
Current ratio5.1×+0.2×

Where this comes from

Reported directly by Merit Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Merit Medical Systems’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merit Medical Systems's therapeutic — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merit Medical Systems's therapeutic — revenue?
Merit Medical Systems (MMSI) reported therapeutic — revenue of $126.4M in Q1 2026.
What does therapeutic — revenue mean?
This metric represents the total net revenue generated from the sale of products or services within the therapeutic business unit, excluding any sales-based taxes collected from customers. It serves as a primary indicator of the commercial performance and market adoption of the company's specialized therapeutic medical devices. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the firm's specific therapeutic product portfolio.